Get access

Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas

Authors

  • P. Rivera,

    1. Department of Clinical Sciences, Center of Clinical Comparative Oncology (C3O), Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden
    Search for more papers by this author
  • N. Åkerlund-Denneberg,

    1. Department of Clinical Sciences, Center of Clinical Comparative Oncology (C3O), Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden
    2. Jönköping Small Animal Hospital, Jönköping, Sweden
    Search for more papers by this author
  • K. Bergvall,

    1. Department of Clinical Sciences, Center of Clinical Comparative Oncology (C3O), Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden
    2. Djurakuten, Stockholm, Sweden
    Search for more papers by this author
  • M. Kessler,

    1. Department of Clinical Sciences, Center of Clinical Comparative Oncology (C3O), Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden
    2. Tierklinik, Hofheim, Germany
    Search for more papers by this author
  • A. Rowe,

    1. Department of Clinical Sciences, Center of Clinical Comparative Oncology (C3O), Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden
    2. Specialist Veterinary Hospital, Strömsholm, Sweden
    Search for more papers by this author
  • M. Willmann,

    1. Department of Clinical Sciences, Center of Clinical Comparative Oncology (C3O), Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden
    2. Department for Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine, Vienna, Austria
    Search for more papers by this author
  • G. Persson,

    1. Department of Clinical Sciences, Center of Clinical Comparative Oncology (C3O), Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden
    2. Region Animal Hospital, Helsingborg, Sweden
    Search for more papers by this author
  • G. Kastengren Fröberg,

    1. Department of Clinical Sciences, Center of Clinical Comparative Oncology (C3O), Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden
    2. Animal Hospital Albano, Danderyd, Sweden
    Search for more papers by this author
  • S. Westberg,

    1. Department of Clinical Sciences, Center of Clinical Comparative Oncology (C3O), Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden
    2. University Animal Hospital, SLU, Uppsala, Sweden
    Search for more papers by this author
  • H. von Euler

    1. Department of Clinical Sciences, Center of Clinical Comparative Oncology (C3O), Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden
    Search for more papers by this author

Abstract

Objective

To determine the clinical efficacy and safety of a cremophor-free formulation of paclitaxel (Paccal Vet, Oasmia Pharmaceuticals) in dogs with mast cell tumours.

Methods

Paccal Vet was administered at a median dose of 145 (range, 135 to 150) mg/m2intravenously once every 21 days for three cycles to 29 dogs with macroscopic grade 2 or 3 mast cell tumour. Efficacy was assessed by tumour response (Response Evaluation Criteria in Solid Tumours version 1.0) and performance status score. Progression-free survival, quality of life and safety/adverse events were also evaluated. Clinical safety was assessed by clinicopathological analyses and recording of adverse events.

Results

Complete or partial response was observed in 59% of dogs. Performance status score remained constant or improved for 20 dogs and decreased by one grade for 9 dogs. Median time to progression was 247 (range, 42 to 268) days. Expected, transient frequently subclinical adverse events (primarily grade 3/4 neutropenia and grade 1/2 leukopenia) were observed in the majority of dogs. Nine dogs were euthanased and one dog died due to disease progression.

Clinical Significance

Paccal Vet appears to be a clinically safe and effective treatment for canine mast cell tumours. Further controlled confirmatory investigation is warranted.

Ancillary